{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:01:50Z","timestamp":1790503310107,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejso.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T11:28:20Z","timestamp":1466422100000},"page":"252-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?"],"prefix":"10.1016","volume":"43","author":[{"given":"P.A.","family":"van Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-9747","authenticated-orcid":false,"given":"A.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2007.10.005","article-title":"Evolving role of uPA\/uPAR system in human cancers","volume":"34","author":"Dass","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2016.06.002_bib2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1517\/13543784.9.9.2085","article-title":"Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin","volume":"9","author":"Dunbar","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejso.2016.06.002_bib3","first-page":"238","article-title":"Clinical relevance of the plasminogen activator inhibitor type 1 \u2013 a multifaceted proteolytic factor","volume":"24","author":"Harbeck","year":"2001","journal-title":"Onkologie"},{"key":"10.1016\/j.ejso.2016.06.002_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13058-014-0428-4","article-title":"uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies","volume":"16","author":"Duffy","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejso.2016.06.002_bib5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6690278","article-title":"Prognostic significance of UPA and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc","volume":"79","author":"Kuhn","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2016.06.002_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0","article-title":"Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage ovarian cancer patients","volume":"79","author":"Chambers","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2016.06.002_bib7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/bjs.1800841206","article-title":"Prognostic factors in gastric cancer","volume":"84","author":"Allayer","year":"1997","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2016.06.002_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00268-002-4050-8","article-title":"Plasmin\/plasminogen system in colorectal cancer","volume":"26","author":"Berger","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2016.06.002_bib9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/02841860801958295","article-title":"A\u00a0comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity in prognostic variable in tumours from 408 patients diagnosed with early breast cancer","volume":"47","author":"Offersen","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejso.2016.06.002_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/87.10.751","article-title":"Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer","volume":"87","author":"Foekens","year":"1995","journal-title":"JNCI"},{"key":"10.1016\/j.ejso.2016.06.002_bib11","first-page":"409","article-title":"Plasminogen activator type 1 in blood and tissue extracts of patients with non-small cell lung cancer","volume":"72","author":"Zekanowska","year":"2004","journal-title":"Pneumonol Alergol Pol"},{"key":"10.1016\/j.ejso.2016.06.002_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2490-10-20","article-title":"Type I plasminogen activator inhibitor in clear cell renal cell carcinoma and its impact on angiogenesis, progression and patient survival after radical nephrectomy","volume":"10","author":"Zubac","year":"2010","journal-title":"BMC Urol"},{"key":"10.1016\/j.ejso.2016.06.002_bib13","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/onc.2011.572","article-title":"Ligand-dependent EGFR activation induces coexpression of IL6 and PAI-1 via the NFkB pathway in advanced stage epithelial ovarian cancer","volume":"31","author":"Alberti","year":"2012","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejso.2016.06.002_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/annonc\/mdq462","article-title":"Impact of expression differences of kallikrein-related peptidases and of uPA and PA-1 between primary tumor and omentum metastasis in advanced ovarian cancer","volume":"22","author":"Dorn","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2009.04.031","article-title":"Expression of urokinase plasminogen activator and its receptor in advanced ovarian cancer patients","volume":"114","author":"Wang","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2016.06.002_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erm.11.47","article-title":"Cancer therapy trials employing level-of-evidence forecast cancer biomarkers uPA and its inhibitor PAI-1","volume":"11","author":"Schmitt","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejso.2016.06.002_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/0008-5472.CAN-03-1820","article-title":"Predictive impact of uPA inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer","volume":"64","author":"Manders","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15384047.2014.1001271","article-title":"Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer","volume":"16","author":"Mashiko","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejso.2016.06.002_bib19","first-page":"1337","article-title":"The urokinase receptor as an entertainer of signal transduction","volume":"14","author":"D'Alessio","year":"2009","journal-title":"Front Biosci"},{"key":"10.1016\/j.ejso.2016.06.002_bib20","first-page":"3958","article-title":"Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor and inhibitors types 1 and 2","volume":"55","author":"Schmalfeldt","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2016.06.002_bib21","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/emboj\/16.10.2610","article-title":"Recycling of the urokinase receptor upon internalization of the uPA-serpin complexes","volume":"16","author":"Nykjaer","year":"1997","journal-title":"EMBO J"},{"issue":"26","key":"10.1016\/j.ejso.2016.06.002_bib22","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1182\/blood-2011-12-399659","article-title":"Inhibition of PAI-1 induces neutrophil driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice","volume":"119","author":"Tashiro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejso.2016.06.002_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/261595a0","article-title":"Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture","volume":"261","author":"Astedt","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.ejso.2016.06.002_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3892\/or.2012.2148","article-title":"Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance","volume":"29","author":"Zhang","year":"2013","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.ejso.2016.06.002_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjc.6605185","article-title":"Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression","volume":"101","author":"Chen","year":"2009","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2016.06.002_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jso.20494","article-title":"Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma","volume":"93","author":"Eltabbakh","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2016.06.002_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2009.10.069","article-title":"When never-events occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes","volume":"116","author":"Duska","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2016.06.002_bib28","doi-asserted-by":"crossref","first-page":"e22469","DOI":"10.1371\/journal.pone.0022469","article-title":"Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma","volume":"6","author":"Trinh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2016.06.002_bib29","first-page":"19","article-title":"Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K\/AKTpathway","volume":"31","author":"Gondi","year":"2007","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2016.06.002_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/aogs.12333","article-title":"Single-dose tranexamic acid in advanced ovarian cancer surgery reduces bloodloss and transfusions: double-blind placebo controlled randomized multicenter study","volume":"93","author":"Lundin","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejso.2016.06.002_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0090-8258(86)90026-0","article-title":"The inhibitory effect of tranexamic acid on human ovarian carcinoma cells grown in\u00a0vitro and in\u00a0vivo","volume":"2","author":"Kikuchi","year":"1986","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2016.06.002_bib32","first-page":"592","article-title":"Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation","volume":"47","author":"Kikuchi","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2016.06.002_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/00016348309155805","article-title":"Tranexamic acid for the treatment of advanced ovarian carcinoma","volume":"62","author":"Sigurdson","year":"1983","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejso.2016.06.002_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/00016348609157383","article-title":"Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amounts of ascites","volume":"65","author":"Kikuchi","year":"1986","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejso.2016.06.002_bib35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/bjc.1982.220","article-title":"Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma","volume":"46","author":"Tanaka","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2016.06.002_bib36","first-page":"295","article-title":"Influence of tranexamic acid on tumour vascularisation. An experimental microangiographic study","volume":"1","author":"Sundbeck","year":"1981","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejso.2016.06.002_bib37","first-page":"559","article-title":"Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice","volume":"57","author":"Jankun","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/B:CLIN.0000024751.73174.c2","article-title":"A\u00a0soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation","volume":"21","author":"Kobayashi","year":"2004","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ejso.2016.06.002_bib39","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood.V90.7.2738","article-title":"Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator type I (PAI-1) in an athymic mouse model","volume":"90","author":"Ma","year":"1997","journal-title":"Blood"},{"issue":"1\u20133","key":"10.1016\/j.ejso.2016.06.002_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0014-5793(02)03311-2","article-title":"High-affinity urokinase-derived cyclic peptides inhibiting urokinase\/urokinase receptor-interaction: effects on tumor growth and spread","volume":"528","author":"Sato","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ejso.2016.06.002_bib41","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1172\/JCI118323","article-title":"Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor associated angiogenesis and metastasis to lung and liver in an athymic mouse modek","volume":"96","author":"Soff","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ejso.2016.06.002_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/156800909787314002","article-title":"The urokinase plasminogen activator system: a target for anti-cancer therapy","volume":"9","author":"Ulisse","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.ejso.2016.06.002_bib43","doi-asserted-by":"crossref","first-page":"e85349","DOI":"10.1371\/journal.pone.0085349","article-title":"Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b","volume":"\u00e7","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejso.2016.06.002_bib44","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1535-7163.MCT-13-0204","article-title":"Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy","volume":"12","author":"Zhang","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ejso.2016.06.002_bib45","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/1535-7163.MCT-13-0500","article-title":"Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model","volume":"12","author":"Gomes-Giacoia","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ejso.2016.06.002_bib46","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/carcin\/bgn028","article-title":"Plasminogen activator inhibitor-1 (PAI-1) blockers suppress intestinal polyp formation in Min mice","volume":"29","author":"Mutoh","year":"2008","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.ejso.2016.06.002_bib47","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1535-7163.MCT-06-0315","article-title":"A\u00a0urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types","volume":"5","author":"Abi-Habib","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/protein\/gzh023","article-title":"A\u00a0bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model","volume":"17","author":"Todhunter","year":"2004","journal-title":"Protein Eng Des Sel"},{"issue":"4","key":"10.1016\/j.ejso.2016.06.002_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/cncr.20034","article-title":"Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer","volume":"100","author":"Kobayashi","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2016.06.002_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1593\/neo.07544","article-title":"PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor","volume":"9","author":"Devy","year":"2007","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.ejso.2016.06.002_bib51","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(02)00866-3","article-title":"A\u00a0selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis","volume":"63","author":"Lee","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib52","first-page":"342","article-title":"The geldanamycins are potent inhibitors of the hepatocyte growth factor\/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network","volume":"60","author":"Webb","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2016.06.002_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0014-5793(94)01032-3","article-title":"Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells","volume":"353","author":"Wang","year":"1994","journal-title":"FEBS Lett"},{"issue":"11","key":"10.1016\/j.ejso.2016.06.002_bib54","first-page":"2553","article-title":"Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor","volume":"53","author":"Towle","year":"1993","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2016.06.002_bib55","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1535-7163.MCT-06-0520","article-title":"Identification of a novel inhibitor of urokinase-type plasminogen activator","volume":"6","author":"Zhu","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.ejso.2016.06.002_bib56","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1073\/pnas.97.10.5113","article-title":"(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase","volume":"97","author":"Sperl","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejso.2016.06.002_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/625176","article-title":"Application of molecular modeling to urokinase inhibitors development","volume":"2014","author":"Sulimov","year":"2014","journal-title":"Biomed Res Int"},{"issue":"46","key":"10.1016\/j.ejso.2016.06.002_bib58","doi-asserted-by":"crossref","first-page":"38424","DOI":"10.1074\/jbc.M505933200","article-title":"A\u00a0urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition","volume":"280","author":"Hansen","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.ejso.2016.06.002_bib59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4161\/cbt.7.5.5643","article-title":"Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor","volume":"7","author":"Hu","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"10.1016\/j.ejso.2016.06.002_bib60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/01.ATV.18.5.693","article-title":"Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding","volume":"18","author":"Quax","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ejso.2016.06.002_bib61","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2012.03.023","article-title":"A\u00a0phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"125","author":"Gold","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2016.06.002_bib62","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdn412","article-title":"Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study","volume":"19","author":"Villalona-Calero","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2016.06.002_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-5793(94)80259-9","article-title":"Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (UPA)inhibition of proliferation and invasion of human ovarian cancer cells","volume":"337","author":"Wilhelm","year":"1994","journal-title":"FEBS Lett"},{"issue":"S2","key":"10.1016\/j.ejso.2016.06.002_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1081\/CNV-200030115","article-title":"First-line therapy for ovarian carcinoma: what's next","volume":"22","author":"Thigpen","year":"2004","journal-title":"Cancer Investig"},{"issue":"9","key":"10.1016\/j.ejso.2016.06.002_bib65","doi-asserted-by":"crossref","first-page":"e0139026","DOI":"10.1371\/journal.pone.0139026","article-title":"Maintenance therapy in ovarian cancer with targeted agents improves PFS and OS: a systematic review and meta-analysis","volume":"10","author":"Qian","year":"2015","journal-title":"PLoS One"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316301937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316301937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T23:47:24Z","timestamp":1656719244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798316301937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0748798316301937"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.06.002","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}